Baird Medical Stock Price, News & Analysis

Baird Medical (NASDAQ: BDMD) recently hosted Dr. Gary G. Tse, an interventional radiologist from UCLA Health, for a clinical visit in Guangzhou, China. The visit showcased the company's advanced microwave ablation (MWA) technology for minimally invasive thyroid treatments.

During the visit at Sun Yat-sen University Cancer Center, Dr. Tse observed multiple thyroid nodule ablation procedures using Baird Medical's MWA system. The visit also included academic discussions with Dr. Michael Mingzhao Xing from Johns Hopkins University School of Medicine, focusing on advancements in thyroid nodule management.

Baird Medical (NASDAQ: BDMD) has achieved a significant expansion milestone as the FDA issued a Certificate to Foreign Government for Egyptian regulatory authorities, validating their compliance with U.S. medical device standards. The company has submitted regulatory registration applications in multiple Asian and Middle Eastern markets including Egypt, Hong Kong, Thailand, Malaysia, Kazakhstan, Sri Lanka, and India.

Following their March 2025 regulatory approval in Indonesia, Baird Medical is establishing partnerships with healthcare institutions across these regions to develop distribution networks and training programs for their microwave ablation (MWA) technology. This minimally invasive procedure, used in treating thyroid nodules and tumors, employs targeted microwave energy for precise ablation with high efficiency and effective hemostasis, while minimizing damage to healthy tissues.

Baird Medical (NASDAQ: BDMD) hosted Dr. Quan-Yang Duh, Chief of Endocrine Surgery at UCSF, for a clinical observation visit in Guangzhou and Shenzhen, China. The visit showcased Baird Medical's microwave ablation (MWA) technology in action.

At Sun Yat-sen University Cancer Center, Dr. Duh observed several thyroid ablation cases, including a notable procedure performed by Dr. Feng Han treating bilateral thyroid nodules with a 4 cm lesion. The procedure demonstrated the minimally invasive nature of the MWA system, with the patient remaining awake throughout.

In Shenzhen, Dr. Duh observed additional MWA procedures and delivered a presentation on surgical management of thyroid diseases. The visit included academic discussions with specialists about integrating microwave ablation with surgical approaches.

Baird Medical Investment Holdings (NASDAQ: BDMD) has announced the successful implementation of its microwave ablation (MWA) technology in two endocrine procedures. The procedures were performed by Dr. Saka Kazeem, an endocrinologist with over 30 years of experience.

Dr. Kazeem, using the MWA system for the first time, commended its efficiency and seamless integration into clinical practice, noting its intuitive nature and optimization of procedure time without compromising patient outcomes. Chairwoman Haimei Wu emphasized the technology's value in improving clinical workflows and patient care.

The company has expressed its commitment to expanding its presence and collaborating with medical professionals to advance MWA technology applications.

Baird Medical (NASDAQ: BDMD) has received the prestigious 'Most Valuable Investment Award' at the 10th China Medical Industry Innovation Competition for its innovative AI Tumor Ablation Surgical Robot.

The competition, which showcases breakthrough medical technologies with high investment potential, recognized Baird Medical's leadership in AI-driven tumor ablation technology. The company's surgical robot is designed to enhance precision, automation, and real-time decision-making in microwave ablation (MWA), with the goal of transforming interventional oncology.

Chairwoman Haimei Wu emphasized the company's commitment to advancing AI-powered surgical solutions, expressing confidence that their innovation will establish new standards in tumor ablation and improve patient outcomes globally. Baird Medical continues to focus on accelerating the development and commercialization of this groundbreaking technology.

Baird Medical (NASDAQ: BDMD) has received the 'Most Valuable Investment Award' at the 10th China Medical Industry Innovation Competition for its innovative AI Tumor Ablation Surgical Robot. The system integrates multimodal AI algorithms with high-precision robotic arm control, featuring autonomous decision-making and dynamic optimization capabilities.

Key technological advantages include:

• Integration of over 100,000 tumor ablation image cases and 50,000 pathology reports
• Federated learning technology enabling secure global data sharing
• Future quantum-optimized pretraining capabilities

The project combines expertise from Nanyang Technological University, oncologic surgeons, and AI engineers from the Chinese Academy of Sciences, with over 90 filed patents. The system will undergo clinical simulations across 20 top-tier hospitals globally and includes an AI-powered surgical ethics decision module targeting surgical complications below 1%. Applications extend beyond tumor ablation to neurosurgery and urology, with planned regulatory approvals in 30+ countries.

Baird Medical Investment Holdings (NASDAQ: BDMD) has secured regulatory approval from the Indonesian Ministry of Health for its microwave ablation (MWA) technology. The approval covers two key products: the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle.

The company's MWA technology is a minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue while minimizing impact on surrounding areas. This technology is particularly effective in treating thyroid nodules and tumors, offering benefits such as enhanced precision and faster recovery times.

Following this regulatory milestone, Baird Medical plans to expand its distribution network and collaborate with medical institutions across Indonesia, advancing its global strategic expansion in emerging markets.

Baird Medical (NASDAQ: BDMD), a medical device company specializing in AI-powered surgical robotics and microwave ablation (MWA) technology, showcased its innovations at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah.

The company's booth attracted significant physician interest, featuring hands-on thyroid phantom demonstrations that highlighted their MWA technology's precision, safety, and efficiency. Company experts engaged with attendees in detailed discussions about clinical applications and practical insights regarding MWA in thyroid care.

The event, which focuses on advancing minimally invasive treatments for thyroid and parathyroid disorders, provided Baird Medical an opportunity to reinforce its position in next-generation thyroid ablation therapies. The company plans to utilize insights gained from NASOIE 2025 to further enhance its MWA technology for thyroid treatment solutions.

Baird Medical Investment Holdings (NASDAQ: BDMD) hosted a delegation of Bangladeshi physicians at its Guangzhou headquarters for an expert-led microwave ablation (MWA) training program. The delegation included four doctors who participated in theoretical discussions and hands-on demonstrations at Baird's facility.

The training continued at Sun Yat-sen University Cancer Center, where participants observed live MWA procedures for liver and lung ablations, followed by discussions with specialists. The program concluded with a session on thyroid microwave ablation techniques led by Dr. Feng Han in the hospital's Ultrasound Department.

Chairwoman Haimei Wu emphasized the company's commitment to global knowledge-sharing and medical innovation through cross-border collaboration.